Amgen (AMGN)
(Delayed Data from NSDQ)
$319.66 USD
+2.18 (0.69%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $319.25 -0.41 (-0.13%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$319.66 USD
+2.18 (0.69%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $319.25 -0.41 (-0.13%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum C VGM
Zacks News
Amgen (AMGN) Beats Q2 Earnings Estimates, to Buy Chemocentryx
by Zacks Equity Research
Amgen (AMGN) beats Q2 estimates for earnings and sales. It offers to buy ChemoCentryx (CCXI) for $3.7 billion.
Amgen (AMGN) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Amgen (AMGN) delivered earnings and revenue surprises of 5.68% and 0.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug, Biotech Stocks' Q2 Earnings on Aug 4: LLY, AMGN & More
by Kinjel Shah
Let us look at four large drug and biotech companies, AMGN, VRTX, LLY, NVO, which are gearing up for their earnings release.
Analysts Estimate Heska (HSKA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Heska (HSKA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amgen (AMGN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Xgeva, Repatha, and others is expected to have been partially offset by biosimilar/generic competition for mature drugs.
AbbVie's (ABBV) Q2 Earnings Beat Estimates, Revenues Lag
by Zacks Equity Research
AbbVie's earnings (ABBV) beat estimates for second-quarter 2022, while sales miss the same. ABBV's immunology and neuroscience drugs drive sales. Shares decline in pre-market trading.
Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $249.75, marking a -0.78% move from the previous day.
Pfizer (PFE) Q2 Earnings Top, COVID Products Drive Sales
by Zacks Equity Research
Pfizer (PFE) beats estimates for Q2 earnings and sales. It maintains the sales forecast for COVID products, Comirnaty and Paxlovid.
Amgen (AMGN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Buy Beaten-Down Biotech Stocks & ETFs?
by Neena Mishra
We highlight 4 ETFs that have started rebounding after a brutal sell-off
Amgen (AMGN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed at $245.95 in the latest trading session, marking a +0.07% move from the prior day.
Healthcare ETFs in Focus Ahead of Q2 Earnings
by Sweta Killa
The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfolio.
Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed the most recent trading day at $246.63, moving -0.28% from the previous trading session.
Is Trending Stock Amgen Inc. (AMGN) a Buy Now?
by Zacks Equity Research
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
The Zacks Analyst Blog Highlights Eli Lilly, Thermo Fisher Scientific, TotalEnergies, Amgen and Marathon Petroleum
by Zacks Equity Research
Eli Lilly, Thermo Fisher Scientific, TotalEnergies, Amgen and Marathon Petroleum have been included in this Analyst Blog.
Top Stock Reports for Eli Lilly, Thermo Fisher & TotalEnergies
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Thermo Fisher Scientific Inc. (TMO), and TotalEnergies SE (TTE).
Why Amgen (AMGN) Could Beat Earnings Estimates Again
by Zacks Equity Research
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Amgen (AMGN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $245.59, marking a -0.61% move from the previous day.
Amgen (AMGN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $247.09, marking a +0.05% move from the previous day.
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Radius (RDUS) Randomizes Patient in Prader-Willi Syndrome Study
by Zacks Equity Research
Radius (RDUS) randomizes the first patient in the SCOUT-015 study of pipeline candidate, RAD011, for Prader-Willi Syndrome.
Amgen (AMGN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $247.42, marking a +0.88% move from the previous day.
Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SCHD